As the U.S. health tech scene heats up—exemplified by Function Health's recent capital raise that catapulted its valuation to a staggering US$2.5 billion—eyes are turning eastward to Singapore, where the stars are aligning for a similar revolution in preventative and longevity medicine. While Silicon Valley grabs headlines, the Lion City is quietly positioning itself as Asia's indispensable hub, blending government foresight, academic prowess, and innovative startups to serve a market of billions hungry for extended healthspans.
At the heart of this surge is Singapore's bold public investment strategy. Just last week, the government unveiled a S$37 billion commitment under the Research, Innovation and Enterprise (RIE) 2030 plan, channeling funds into "grand challenges" like healthy longevity and precision medicine. This isn't mere rhetoric; it's infrastructure in action, with Biopolis—a state-of-the-art biotech cluster—fostering breakthroughs in geroscience and attracting global talent. As Asia grapples with an aging population projected to swell to over 1 billion seniors by 2050, Singapore's proactive stance signals a blueprint for scalable, data-driven health solutions.
Leading the charge academically is the National University of Singapore (NUS), a regional powerhouse in geroscience research. Through its Academy for Healthy Longevity, NUS is pioneering precision geromedicine—shifting from reactive treatments to proactive interventions that target aging at its roots. Recent milestones include the launch of a dedicated clinical trial center in October 2025, partnering with industry giants like Haleon and Abbott to accelerate multimodal studies on healthspan optimization. NUS's efforts, including public surveys revealing strong demand for subsidized preventive screenings, underscore a cultural shift: Singaporeans aren't just living longer—they're demanding to thrive longer.
Enter players like i-screen, the Australian-born health tech disruptor that's betting big on Singapore as its Asian launchpad. Founded in 2015, i-screen has already empowered over 113,000 users with accessible pathology testing, from blood biomarkers to microbiome analysis, all via an intuitive digital dashboard that demystifies personal health data. On December 9, 2025—just days ago—the company unveiled i-screen.sg, establishing the city-state as its Southeast Asia headquarters under new CEO Scott Montgomery, a veteran steering expansion into high-growth markets like integrative medicine and wellness. With offerings like biological age assessments and genetic screenings for longevity traits, i-screen taps into Asia's voracious appetite for holistic, evidence-based care—think TCM practitioners, fitness coaches, and insurers all converging on preventive insights.
Yet, to unlock Asia's trillion-dollar longevity potential, Singapore needs more i-screens: agile tech firms scaling clinical-grade tools for the masses. The region's 4.7 billion residents, increasingly affluent and health-literate, are fueling demand for integrative approaches that blend Eastern wellness with Western data science. As Function Health proves stateside, unicorn valuations follow innovation that democratizes health. Singapore, with its regulatory agility and talent pipeline, is primed to birth the next wave—pinned on trailblazers like i-screen leading the charge.
In a world racing against time, Singapore isn't just investing in longevity; it's engineering it. The question isn't if Asia will follow—it's who will join the vanguard.
Contact details:
For further information - Contact:
Jane Morgan:
